Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D (2010) J Clin Oncol 28: 1843-9 Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Linkous A, Geng L, Lyshchik A, Hallahan DE, Yazlovitskaya EM (2009) Clin Cancer Res 15: 1635-44 Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels. Ji C, Marnett LJ, Pietenpol JA (1997) Oncogene 15: 2749-53 Role of p63 amplification and overexpression in lung cancer development. Massion PP, Taflan PM, Rahman SM, Yildiz P, Shyr Y, Carbone DP, Gonzalez AL (2004) Chest 125: 102S Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Ji C, Rouzer CA, Marnett LJ, Pietenpol JA (1998) Carcinogenesis 19: 1275-83 A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Choy H, Devore RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) Int J Radiat Oncol Biol Phys 47: 931-7 Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Kong FM, Anscher MS, Sporn TA, Washington MK, Clough R, Barcellos-Hoff MH, Jirtle RL (2001) Int J Radiat Oncol Biol Phys 49: 35-41 Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. Taylor NA, Liao ZX, Stevens C, Walsh G, Roth J, Putnam J, Fossella F, Allen P, Cox JD, Komaki R (2003) Int J Radiat Oncol Biol Phys 56: 616-25 Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM, Massion PP (2007) J Thorac Oncol 2: 893-901
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.